In accordance with the resolution at the Annual General Meeting of Probi AB (publ) on May 7, 2021, the number of shares and votes in Probi has decreased during May 2021 through the cancellation of 250,000 own shares.
Prior to the cancellation of own shares, there were a total of 11,644,125 shares and votes in Probi. The number of shares and votes decreased through the withdrawal by 250,000. Following the completion of the withdrawal, there are a total of 11,394,125 shares and votes in Probi as of May 31, 2021.
For further information, please contact:
Henrik Lundkvist, CFO: tel + 46 46 286 89 41, e-mail: firstname.lastname@example.org
This information is information that Probi is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out below, at 8.00 CET on 31 May 2021.
Probi[®] is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. The company is an expert in managing stable, live bacteria from research through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 717 m in 2020. Probi's shares are listed on Nasdaq Stockholm, Mid-cap. and there were around 4,000 shareholders on December 31, 2020.
This information was distributed by Cision http://www.cisionwire.se/